Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
5(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
5
50%
Ph phase_3
2
20%
Ph phase_1
3
30%

Phase Distribution

3

Early Stage

5

Mid Stage

2

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
3(30.0%)
Phase 2Efficacy & side effects
5(50.0%)
Phase 3Large-scale testing
2(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

5

trials recruiting

Total Trials

10

all time

Status Distribution
Active(6)
Completed(2)
Terminated(1)
Other(1)

Detailed Status

Recruiting4
Completed2
Withdrawn1
Active, not recruiting1
Not yet recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
5
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (30.0%)
Phase 25 (50.0%)
Phase 32 (20.0%)

Trials by Status

withdrawn110%
active_not_recruiting110%
not_yet_recruiting110%
completed220%
recruiting440%
unknown110%

Recent Activity

5 active trials
Showing 5 of 10
recruitingphase_3

A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

NCT07183189
recruitingphase_1

A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer

NCT07130916
recruitingphase_2

A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

NCT06417008
not_yet_recruitingphase_2

Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer

NCT06752408
withdrawnphase_2

Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA).

NCT06227897
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT07183189Phase 3

A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

Recruiting
NCT07130916Phase 1

A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer

Recruiting
NCT06417008Phase 2

A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

Recruiting
NCT06752408Phase 2

Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer

Not Yet Recruiting
NCT06227897Phase 2

Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA).

Withdrawn
NCT04923906Phase 3

Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations

Active Not Recruiting
NCT05946460Phase 2

Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.

Recruiting
NCT04922138Phase 2

Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade Patterns

Unknown
NCT05199610Phase 1

An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143

Completed
NCT04969965Phase 1

To Evaluate the Comparative Pharmacokinetics of Orally Administered EQ143 in Different Racial and Ethnic Populations

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10